A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate
Overview
- Phase
- Not Applicable
- Intervention
- [68Ga]P3
- Conditions
- Neoplasms
- Sponsor
- Peking University First Hospital
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.
[68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Detailed Description
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.\[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Investigators
Xing YANG
Principal Investigator
Peking University First Hospital
Eligibility Criteria
Inclusion Criteria
- •patients with confirmed or suspected cancer; Signed written informed consent
Exclusion Criteria
- Not provided
Arms & Interventions
[68Ga]P3
Subjects with suspected or confirmed Prostate will receive an intravenous injection of 68Ga-P3 followed by PET imaging.
Intervention: [68Ga]P3
Outcomes
Primary Outcomes
The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate
Time Frame: 1 year
the standardized Uptake Value (SUV) of lesions on 68Ga-P3 PET/CT
The detection efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate
Time Frame: 1 year
the number of lesions detected by 68Ga-P3 PET/CT, based on the pathology or clinical follow-up as gold standard.
Secondary Outcomes
- Correlation with pathological expression(1 year)
- The dosimetry of 68Ga-P3(1 year)
- Quantitative evaluation of 68Ga-P3(1 year)